Evidence map›Paper›PMID 35358722›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

Role of procalcitonin as a predictor of clinical outcomes in hospitalized patients with COVID-19.

Ian Jackson, Hadi Jaradeh, Sarah Aurit, Ali Aldamen, Shraddha Narechania, Christopher Destache, Manasa Velagapudi

Open access · goldAbstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Guidelines for the Use of Procalcitonin for Rational Use of Antibiotics.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ian JacksonDepartment of Medicine, Creighton University School of Medicine, 7500 Mercy Road, Omaha, Nebraska, 68124, USA. Electronic address: IanJackson@Creighton.edu.
Hadi JaradehDepartment of Medicine, Creighton University School of Medicine, 7500 Mercy Road, Omaha, Nebraska, 68124, USA.
Sarah AuritDivision of Clinical Research and Evaluative Sciences, Creighton University School of Medicine, 7500 Mercy Road, Omaha, Nebraska, 68124, USA.
Ali AldamenDepartment of Medicine, Creighton University School of Medicine, 7500 Mercy Road, Omaha, Nebraska, 68124, USA.
Shraddha NarechaniaDivision of Pulmonary and Critical Care, Creighton University School of Medicine, 7500 Mercy Road, Omaha, Nebraska, 68124, USA.
Christopher DestacheCreighton University School of Pharmacy and Health Professions, 7500 Mercy Road, Omaha, Nebraska, 68124, USA; Division of Infectious Disease, Creighton University School of Medicine, 7500 Mercy Road, Omaha, Nebraska, 68124, USA.
Manasa VelagapudiDivision of Infectious Disease, Creighton University School of Medicine, 7500 Mercy Road, Omaha, Nebraska, 68124, USA.
Creighton University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn this study, we aimed to determine the correlation between procalcitonin (PCT) levels and clinical outcomes including in-hospital mortality, intensive care unit (ICU) length of stay, and hospital length of stay in patients hospitalized with COVID-19.

methodsClinical, laboratory, and demographic data of 223 patients who met inclusion criteria were analyzed. PCT measurements of 0.25 ng/mL and 0.50 ng/mL were used to stratify patients into 2 mutually exclusive groups.

resultsPatients with PCT above 0.25 ng/mL on admission had significantly elevated Acute Physiology and Chronic Health Evaluation II scores (9 vs 8; P = 0.042) and C-reactive proteins levels (111 μg/mL vs 79 μg/mL; P = 0.007). A multivariable binary logistic regression model demonstrated no relationship between PCT and mortality (OR = 1.00; 95% Cl: 0.97 to 1.02; P = 0.713). Kaplan-Meier analysis revealed no statistical evidence of a difference between PCT groups and hospital length of stay (P = 0.144 for 0.25 ng/mL, P = 0.368 for 0.50 ng/mL) or intensive care unit length of stay (P = 0.986 for 0.25 ng/mL, P = 0.771 for 0.50 ng/mL).

conclusionsElevated PCT levels were associated with severity of illness but did not correlate with in-hospital mortality, hospital length of stay, or ICU length of stay.

Indexed as

COVID-19ProcalcitoninHospital MortalityHumansIntensive Care UnitsPrognosisRetrospective StudiesProcalcitoninClinical outcomesCOVID-19ProcalcitoninPrognosis

Identifiers

PMID35358722
PMCPMC8958767
OpenAlexW4220808920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.